NYSE · LLY
Eli Lilly and Company
$1,412.47+$38.77 (+2.82%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.56% below the high.
Loading market information…
NASDAQ · ELOX · USD
Stock price, earnings
Quote as of Oct 30, 2026, 07:38 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Eloxx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.21% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Eloxx Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of -$0.58. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Eloxx Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:38 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2023 | Apr 3, 2023 | -$32.12-981.48% vs estimate | $0.00 |
|---|
| Q3 2022 | Nov 10, 2022 | -$39.60+18.18% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $38.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,412.47+$38.77 (+2.82%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.56% below the high.
$273.80-$1.40 (-0.51%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.91% below the high.
$293.77+$2.98 (+1.02%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.66% below the high.
$149.67+$3.34 (+2.28%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.62% below the high.
$406.42-$4.49 (-1.09%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 11.96% below the high.
$694.99-$14.19 (-2.0%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.37% below the high.
$466.89+$6.16 (+1.34%)
Amgen Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.86% below the high.
$171.38+$5.77 (+3.48%)
Gilead Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.43% below the high.
